SURPASS trial programme: difference between revisions
Diff·revision 5 → 6·00:53, 3 Sep 2024
Difference between revision 5 and revision 6 of SURPASS trial programme. 3 lines changed; the page grew by 288 bytes.
| Revision 5 — 00:41, 29 Aug 2024 EndpointEnid (talk) label the extension study as an extension study in the table 1,993 bytes ±0 | Revision 6 — 00:53, 3 Sep 2024 CagriCass (talk) fix a dangling clause 2,281 bytes +288 | ||
|---|---|---|---|
| 10 | Glycated-haemoglobin reductions across the programme were larger than those reported for any comparator, reaching about 2.0–2.6 percentage points at the higher doses depending on trial and baseline. Weight reduction accompanied them at every dose.{{r|frias2021}} | 10 | Glycated-haemoglobin reductions across the programme were larger than those reported for any comparator, reaching about 2.0–2.6 percentage points at the higher doses depending on trial and baseline. Weight reduction accompanied them at every dose.{{r|frias2021}} |
| 11 | 11 | ||
| + | 12 | SURPASS-2 is the most cited member because it is a direct head-to-head against semaglutide. The comparator dose was 1 mg — the diabetes dose — not the 2.4 mg used in obesity, a distinction routinely omitted when the trial is summarised.{{r|frias2021}} | |
| + | 13 | ||
| 12 | == Constituent trials == | 14 | == Constituent trials == |
| 13 | | Trial | Comparator | Notes | | 15 | | Trial | Comparator | Notes | |
| ⋮ | ⋮ | ||
| 29 | [[Category:Clinical trial programmes]] | 31 | [[Category:Clinical trial programmes]] |
| 30 | [[Category:Type 2 diabetes trials]] | 32 | [[Category:Type 2 diabetes trials]] |
| + | 33 | [[Category:Clinical evidence]] | |
| 31 | 34 |